ABSTRACT Introduction Glucagon-like peptide-1 (GLP-1) is an endogenous peptide which
is secreted by enteroendocrine L cells, GLP-1 receptor agonists (GLP-1 RAs) can exhibit …

Introduction: Obesity is a worldwide problem predisposing to type 2 diabetes mellitus
(T2DM), hypertension, cardiovascular disease, cancer and other comorbidities. Lifestyle …

Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as
promising therapeutic options for addressing Type‐2 diabetes, obesity, and related …

Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor
agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in …

Purpose Published data on the weight loss effects of glucagon-like peptide 1 (GLP-1)
receptor agonists are reviewed, with a focus on data from clinical trials. Summary Obesity is …

Obesity is a chronic disease associated with many complications. Weight loss of 5–15% can
improve many obesity-related complications. Despite the benefits of weight reduction, there …

Obesity is an important public health issue that has been on the rise over the last decades. It
calls for effective prevention and treatment. Bariatric surgery is the most effective medical …

Abstract Purpose of Review The burden of obesity worldwide is high and projected to rise.
Obesity increases the risk of several cardiovascular diseases and cardiometabolic risk …

There is a global obesity epidemic that will continue to be a financial burden on healthcare
systems around the world. Tackling obesity through diet and exercise should always be the …

Highlights•GLP-1 analogues are used in the management of type 2 diabetes and
obesity.•They improve glycaemic control, promote weight loss and have a low risk of …